Sequence variation in PPARG may underlie differential response to troglitazone. - Wikidata - awgldk - TriplyDB

Sequence variation in PPARG may underlie differential response to troglitazone.

Sequence variation in PPARG may underlie differential response to troglitazone.

http://www.wikidata.org/entity/Q34072562

about

DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes Exercise training, genetics and type 2 diabetes-related phenotypes.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Clinical translation of genetic predictors for type 2 diabetes.Pharmacogenetics of Anti-Diabetes Drugs.Inherited destiny? Genetics and gestational diabetes mellitus.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Pharmacogenetics in type 2 diabetes: potential implications for clinical practice Type 2 Diabetes Genetics: Beyond GWAS.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.Pharmacogenetics of thiazolidinedione therapy.Pharmacogenetics of the PPAR genes and cardiovascular disease.Pharmacogenetics: potential role in the treatment of diabetes and obesity PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.Personalized pharmacotherapy for Type 2 diabetes mellitus.Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains.Genetic susceptibility to type 2 diabetes and implications for therapy.The genetics of type 2 diabetes: what have we learned from GWAS?Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.The genetics of type 2 diabetes and its clinical relevance.Pharmacogenetics for type 2 diabetes: practical considerations for study design.Pharmacogenomics of metabolic effects of rosiglitazone.Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies

P2860

Q28649649-FB0E1D84-B7AC-4D64-AAE2-867A57514F27 Q30417635-71248211-9E92-491F-B433-140B0058200E Q30571118-4E06389B-B8AF-4966-BDE6-AAD207C08FDE Q33993320-63DD0CA7-7E9D-45BA-BDA0-85E4285626B8 Q34124681-673F43B5-D7A3-4A92-B7B9-4C1D08D8DEE6 Q34181995-5D903B25-B76D-467B-A80D-142D333975A0 Q34971477-62C77993-95AB-4800-99DB-C6C070BFE2FF Q35039274-839463C0-094C-4013-8CF0-F726604FD1A5 Q35840645-90E72D32-E44F-48A1-85AB-4AED9BD04505 Q36464788-721AE1DA-A84B-4ED5-A9C5-3FC14184CBBD Q36475040-12BB1CAF-4E18-46DA-92DE-0675F3BA764B Q36496755-1EB990E3-7EC3-4D5F-A696-3F80FFFE0F51 Q36528512-D4C5F291-DB87-4960-A38D-B26618CAFA92 Q36573908-759C8C8B-4817-4D7C-A53F-93DDBE5F7197 Q36845108-139F322A-53DB-4CCC-9ABB-DF3E13828551 Q36918107-844642F6-D32E-4E0E-91AC-DFEE18571FC7 Q37012017-9AABEB94-1DC6-43B0-9032-BB1D74120E2B Q37142047-04F73167-00F8-40EB-B565-A44287E0CA19 Q37238001-4662DD1E-42E3-437E-AAC7-8821C7B3D475 Q37365702-726B77BE-092A-4F1F-B340-0A74B43F5E68 Q37439788-5F619E40-B168-49E7-A68F-8A535E64CEB7 Q37689851-578BD3EC-060F-4909-90BC-4BA1D87753D9 Q37811045-1781515A-A746-453E-AFF0-5E382A3131CA Q37822185-CFBC7B10-1058-41E3-B66D-9EF8CE0391A7 Q38061186-D74FE079-5676-4ED6-BA93-8703984E7DAD Q42599734-309C800C-FB20-4295-BE15-28EB0B6E7820 Q46679104-08B758F5-F4F0-4FAE-8E04-8EDFA0E29B74 Q46794502-26890650-CEB5-41AC-92CE-948749FF5E9E Q57701985-C7891A6D-A1E0-44E0-A581-E6747AF7166A

P2860

Sequence variation in PPARG may underlie differential response to troglitazone.

http://www.wikidata.org/entity/Q34072562

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Sequence variation in PPARG may underlie differential response to troglitazone.

@ast

Sequence variation in PPARG may underlie differential response to troglitazone.

@en

Sequence variation in PPARG may underlie differential response to troglitazone.

@nl

type

label

Sequence variation in PPARG may underlie differential response to troglitazone.

@ast

Sequence variation in PPARG may underlie differential response to troglitazone.

@en

Sequence variation in PPARG may underlie differential response to troglitazone.

@nl

prefLabel

Sequence variation in PPARG may underlie differential response to troglitazone.

@ast

Sequence variation in PPARG may underlie differential response to troglitazone.

@en

Sequence variation in PPARG may underlie differential response to troglitazone.

@nl

P1433

Q34072562-8C26800B-C414-419A-9CFC-48D56A78AA0B

P1476

Q34072562-C410B444-ACC8-4CA5-BC48-5C30DEFD206D

P2093

Q34072562-2677B221-BC40-4E55-A3FA-0356678B718B

Q34072562-78222CC9-75AB-445D-8D6E-6CA311301586

Q34072562-795AB1A7-DAA7-4E09-8C86-3A8910A5DCE7

Q34072562-9573A9E7-CCE1-47B1-955F-B7EBB13E627D

Q34072562-C2555AE7-EDD4-480F-A966-95AC3242E5BC

Q34072562-F1338E65-4544-4440-9A6F-521270F1E66F

Q34072562-FCBAABCD-CD6A-4EFF-A06A-11F790E67085

P2860

Q34072562-14226F7A-3A33-4684-AFC5-CE209298F047

Q34072562-1E608FF9-007C-4EC9-BE91-C321D9A8A4B5

Q34072562-227732AD-8C48-4187-93F4-EF348D2CBDBC

Q34072562-29927634-A21B-4885-8E4A-2DA286A34F23

Q34072562-37244C2C-EE47-4CC3-8D71-6F3A8033F7AD

Q34072562-3C8C32AB-9CCC-481A-8534-212B3741A2BE

Q34072562-3FCAD194-BA5B-4F5A-BC94-2F2E8AD01624

Q34072562-521E15C7-0EC9-44AC-B7A2-E4E6512BEACE

Q34072562-6202006D-2630-4EBD-ADCA-35C18DE411E1

Q34072562-68EE19B2-04F1-417D-9E4E-29010E2DCE0F

P304

Q34072562-4C8084C4-2120-4B03-AE6B-3C15D9AAB8A0

P31

Q34072562-767BAC2A-D8DF-4687-BABB-E4D2D19435BD

P356

Q34072562-AC67C0D0-1561-4EF9-80E6-85198E23C966

P407

Q34072562-28AA83F8-A7AA-4D5B-B48E-964F5DB75D31

P433

Q34072562-1EF5F320-F7E8-49E0-9E87-DF051A8747FD

P478

Q34072562-3BF4F0F1-B561-4C63-89CF-4F177ADB7348

P577

Q34072562-964A9E01-B61F-4215-B693-BFA6D46C826D

P5875

Q34072562-CB8D9191-462F-4909-AB10-13EC7A8B518E

P698

Q34072562-BA2AE503-BCE3-4A27-858D-30A27FA1F16B

P932

Q34072562-CC9E6545-5A6E-41E7-94C0-20AB32D6AB34

P356

DIABETES.54.11.3319

P1433

P1476

Sequence variation in PPARG may underlie differential response to troglitazone.

@en

P2093

Anny H Xiang

http://www.w3.org/2001/XMLSchema#string

Johanna K Wolford

http://www.w3.org/2001/XMLSchema#string

Kimberly A Yeatts

http://www.w3.org/2001/XMLSchema#string

Mary Helen Black

http://www.w3.org/2001/XMLSchema#string

Richard M Watanabe

http://www.w3.org/2001/XMLSchema#string

Sharanjeet K Dhanjal

http://www.w3.org/2001/XMLSchema#string

Thomas A Buchanan

http://www.w3.org/2001/XMLSchema#string

P2860

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action

The structure of haplotype blocks in the human genome

Haploview: analysis and visualization of LD and haplotype maps

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Pioglitazone: a review of Japanese clinical studies.

Differentiating members of the thiazolidinedione class: a focus on efficacy.

Novel insulin sensitizers: pharmacogenomic aspects.

Inference of haplotypes from PCR-amplified samples of diploid populations.

P304

3319-3325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.54.11.3319

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7518107

http://www.w3.org/2001/XMLSchema#string

P698

16249460

http://www.w3.org/2001/XMLSchema#string

P932

2923445

http://www.w3.org/2001/XMLSchema#string